Carboxyl Gold Nanospheres
Formulated for attachment of a molecular recognition element
Starting at $150
Development of competitive and sandwich assay formats for protein hormones, steroid hormones, protein/protein complexes, peptide, serological response (IgM and IgG antibodies), drugs of abuse, fungal infection, bacteria, and viruses
Integration with multiple reader technologies for rapid, mobile, and quantitative point of care applications
Over 15 years of manufacturing and optimizing colloidal gold, gold reagents, and robust, reproducible conjugates
Proprietary gold nanoshells for the most sensitive quantitative and semi-quantitative visual detection, eliminating the need for costly filters or lenses
ISO 13485:2016 Certified* and contract manufacturer of prototype lots with up to 50,000 test strips and scaled manufacturing partners worldwide for larger quantities
On-site manufacturing of colloidal gold and gold nanoshells ensure a robust supply chain and enable large-scale production of strips and conjugates
Lateral Flow Services Case Studies
See real case studies on clients we have helped and the projects that needed completing:
CLIENT: FORTUNE 500 PACKAGING COMPANY
The existing standard method of detection for this food safety assay requires multiple days and a skilled scientist to perform the test. Using ultra-sensitive nanoparticle technologies, nanoComposix is developing a rapid lateral flow assay that can identify dangerous bacterial pathogens in less than 10 minutes.
CLIENT: NON-PROFIT ORGANIZATION DEVELOPING ASSAYS FOR DETECTION OF NEGLECTED TROPICAL DISEASES
Using the gold nanoshells, the non-profit group was able to achieve the desired sensitivity for their assay. The assay was transferred to nanoComposix for transfer to scale-up manufacturing under our Quality Management System. The assays were manufactured (50K strips) for testing in third world countries and are currently being evaluated in the field.
CLIENT: MARKET LEADER IN VETERINARY DIAGNOSTICS
This customer turned to nanoComposix after three years of assay development where assay sensitivity could not be achieved by an internal team or with two separate contract assay development manufactures. The first company spent 6-months optimizing the assay and could not reach the required limit of detection. The second development company used proprietary nanobeads which achieved sensitivity but dried conjugate was unstable after 6 weeks. After a one-month effort, nanoComposix achieved the clinically relevant sensitivity using gold nanoshells.
CLIENT: DIAGNOSTIC DEVELOPER
Customer approached us to develop two immunoassays to quantify two biomarkers for a physiological disorder. Although commercial tests (e.g. ELISA) existed for the quantification of these biomarkers, the customer perceived a market need for a simple, fast, and inexpensive method of detection. The initial phase of work successfully identified optimal affinity reagents to create a novel immunoassay for each biomarker. The immunoassays were then used to assess the diagnostic performance of each biomarker in a panel of diseased and non-diseased saliva samples. Following the successful outcome of phase one, the customer engaged with us to develop a multiplexed lateral flow assay to qualitatively detect both biomarkers. This work included the initiation of design controls and the manufacturing of pilot lot of tests.
CLIENT: DIAGNOSTIC INSTRUMENT MANUFACTURER
We were approached to assist in developing a point-of-care lateral flow assay to monitor a therapeutic drug level in patient saliva. During the first phase of work, we successfully identified optimal affinity reagents and developed a conjugation method to attach antibodies with spectroscopic labels to BioReady 150 nm Carboxyl Gold Nanoshells, enabling analyte detection using the client’s spectroscopic platform. Based on a successful phase one, the customer contracted with us for phase two, where the assay will be optimized and design controls will be implemented to produce a prototype device.
We developed and manufactured a lateral flow sandwich assay to detect amplified RNA or DNA fragments (amplicons) labeled with FITC/FAM and Biotin.
To help in the fight against COVID-19, this assay is being used to detect an amplified novel coronavirus (2019-nCoV) target RNA sequence from lysed, heat-inactivated virus samples at decreasing concentrations. Performance of the optimized LAMP-based assay and quantitative detection of the virus DNA product was examined using this device and verified with SYBR nucleic acid intercalating fluorescent dye. Both fluorescence and our assay results agree, confirming the functionality of the LAMP assay. This assay provided an adequate dose-response to enable the determination of quantitative Limit of Detection (LoD) and other key performance metrics. Image results of the dose-response experiment are presented below.
Using BioReady 150 nm Carboxyl Gold Nanoshells as reporter probes, we developed a rapid diagnostic to detect the presence of the Borrelia burgdorferi bacteria in ticks, which when transmitted by tick bites, can lead to Lyme disease.
Leveraging the unique optical properties of BioReady Gold Nanoshells along with nanoComposix’s assay development expertise, our lateral flow test strips provide 4× and 10× lower LOD (Limit of Detection) than similar test kits available on the market, as shown below.
Strips run with Borrelia antigen dilutions and read on a Qiagen benchtop reader.
